PYLARIFY PET-CT Imaging for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you have had chemotherapy, immunotherapy, or radiotherapy within 4 weeks before the trial, you may not be eligible to participate.
Is Piflufolastat F18 (PYLARIFY) safe for use in humans?
Piflufolastat F18 (PYLARIFY) is a diagnostic imaging agent approved by the FDA for use in prostate cancer imaging, indicating it has been evaluated for safety in humans. It is used in PET scans to help detect prostate cancer, and its approval suggests it is generally considered safe for this purpose.12345
How is the drug PYLARIFY PET-CT Imaging for Cancer different from other treatments?
What data supports the effectiveness of the drug Piflufolastat F18 in cancer treatment?
Piflufolastat F18 is effective in imaging prostate cancer by targeting a specific protein found in most prostate cancers, helping doctors better understand the spread and stage of the disease. It has been shown to be more effective than standard imaging methods for detecting prostate cancer and its recurrence.12358
Who Is on the Research Team?
Yang Lu, MD, PHD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
Adults with confirmed pancreatic ductal adenocarcinoma, hepatocellular carcinoma (HCC), or invasive lobular breast cancer who may have metastatic disease. Participants must be able to consent, have a measurable lesion, and an estimated life expectancy of at least 3 months. Pregnant women, those allergic to PSMA PET radiopharmaceuticals, or unable to undergo PET-CT are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive PYLARIFY (piflufolastat F18) PET-CT scans to assess diagnosis accuracy for detecting metastasis
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- Piflufolastat F18
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Lantheus Medical Imaging
Industry Sponsor